Shionogi, a leading Japanese pharmaceutical company, has joined the CMAC consortium, marking a pivotal step in global collaboration and innovation.

Lonza has joined CMAC as a Translation to Industry Collaborator to enhance its service offering for specialty and enhanced drug product and particle technologies

A new £1m research project to realise the transformative potential of digital technologies like artificial intelligence (AI) in medicines development and manufacturing has been announced.

The Centre of Excellence in Regulatory Science and Innovation (CERSI) project aims to advance regulatory processes by integrating cutting-edge digital technologies.

CMAC has appointed John Mack as a new member of its Industry Board. Representing CMAC’s Tier 2 membership, John’s role will enhance the Tier 2 community's connection to CMAC’s activities, ensuring the centre stays at the forefront of manufacturing advancements and continues to meet the evolving needs of its members.

Global CDMO Ajinomoto Bio-Pharma Services has become the first organisation to position itself as a Translation to Industry Collaborator within CMAC, a world-leading centre for medicines manufacturing at the University of Strathclyde.

Together, CMAC and digiM will align to accelerate research and development within CMAC’s ambitious strategy for digital transformation of Chemistry, Manufacturing, and Control (CMC) processes.

CMAC launches campaign encouraging postdoctoral researchers from around the globe, to apply for a prestigious Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.

CMAC staff and students recently gathered at the Hilton Dunblane Hydro Hotel for CMAC’s annual Summer School, a week-long event featuring workshops, seminars, and networking opportunities.

The EPSRC MediForge Hub will transform the development and manufacturing of medicines by pioneering an Industry 5.0 manufacturing system for sustainable, resilient, and human-centric medicine production.

In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, leon-nanodrugs GmbH (LEON), has proudly announced a pioneering technical evaluation by CMAC, University of Strathclyde.

This ground-breaking CDT is set to revolutionise the pharmaceutical and technology sectors by addressing critical skills needs within the industry.

CMAC are thrilled to announce that we have welcomed Malvern Panalytical as a new Tier 2 member within our cutting-edge technology portfolio.

This collaboration marks a significant milestone for the Centre in driving collaborative research and innovation within advanced pharmaceutical manufacturing.

The University of Strathclyde’s medicines manufacturing research centre, CMAC, is delighted to announce the next phase in our strategic partnership with The Glasgow School of Art (GSA).

14.11.23 CMAC DAY 1

The University of Strathclyde’s Continuous Manufacturing and Advanced Crystallisation (CMAC) are delighted to announce a new £11 million award from UK Research Partnership Investment Fund (UKRPIF) to deliver the CMAC Data Lab: A Digital Medicine Manufacturing Research Accelerator. 

The University of Strathclyde’s Continuous Manufacturing and Advanced Crystallisation (CMAC) medicines manufacturing research centre has installed a new NVIDIA DGX H100 supercomputer, becoming the first university centre in the UK to have this groundbreaking platform to enable the next wave of artificial intelligence (AI) research and development. 

Summer School is an annual, week-long programme that provides CMAC students and staff with the opportunity to collaborate with a variety of talented professionals who deliver insightful training throughout the week.

In continuation of our monthly “Meet our Team” post, we are celebrating CMAC’s Operational Coordinator and PA To the Directors, Morell Kerr.